These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 6537120)

  • 21. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network.
    Palumbo A; Falco P; Corradini P; Falcone A; Di Raimondo F; Giuliani N; Crippa C; Ciccone G; Omedè P; Ambrosini MT; Gay F; Bringhen S; Musto P; Foà R; Knight R; Zeldis JB; Boccadoro M; Petrucci MT;
    J Clin Oncol; 2007 Oct; 25(28):4459-65. PubMed ID: 17785703
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Melphalan and its role in the management of patients with multiple myeloma.
    Falco P; Bringhen S; Avonto I; Gay F; Morabito F; Boccadoro M; Palumbo A
    Expert Rev Anticancer Ther; 2007 Jul; 7(7):945-57. PubMed ID: 17627453
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of melphalan in myeloma patients undergoing an autograft.
    Nath CE; Shaw PJ; Trotman J; Zeng L
    Bone Marrow Transplant; 2007 Oct; 40(7):707-8. PubMed ID: 17680022
    [No Abstract]   [Full Text] [Related]  

  • 24. Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients.
    Carreras E; Rosiñol L; Terol MJ; Alegre A; de Arriba F; García-Laraña J; Bello JL; García R; León A; Martínez R; Peñarrubia MJ; Poderós C; Ribas P; Ribera JM; San Miguel J; Bladé J; Lahuerta JJ;
    Biol Blood Marrow Transplant; 2007 Dec; 13(12):1448-54. PubMed ID: 18022574
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bortezomib plus melphalan and prednisone for multiple myeloma.
    Tsubokura M; Kami M; Komatsu T
    N Engl J Med; 2008 Dec; 359(24):2613; author reply 2613-4. PubMed ID: 19090031
    [No Abstract]   [Full Text] [Related]  

  • 26. Acute leukemia secondary to multiple myeloma.
    de Gramont A; Rioux E; Shields C
    Can Med Assoc J; 1983 Sep; 129(6):534, 536. PubMed ID: 6576845
    [No Abstract]   [Full Text] [Related]  

  • 27. [High-dose melphalan in patients with multiple myeloma].
    Moreau P; Le Bonniec M; Harousseau JL
    Bull Cancer; 1999 Mar; 86(3):283-8. PubMed ID: 10210762
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacology of intravenous melphalan in patients with multiple myeloma.
    Brox L; Birkett L; Belch A
    Cancer Treat Rev; 1979 Jun; 6 Suppl():27-32. PubMed ID: 498169
    [No Abstract]   [Full Text] [Related]  

  • 29. [Use of intravenous melphalan in the treatment of Kahler's disease].
    Balmes A; Dauverchain J; Othoniel J; Mandin A; Chavanette F
    Presse Med (1893); 1971 May; 7(23):1072. PubMed ID: 5577947
    [No Abstract]   [Full Text] [Related]  

  • 30. [Acute myeloproliferative syndrome after alkylating agent treatment in a case of multiple myeloma].
    Gardella S; Cervantes F; Bladé J; Brugués R; Rozman C
    Med Clin (Barc); 1982 Sep 1-15; 79(4):185-8. PubMed ID: 7144293
    [No Abstract]   [Full Text] [Related]  

  • 31. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
    Berenson JR; Yang HH; Sadler K; Jarutirasarn SG; Vescio RA; Mapes R; Purner M; Lee SP; Wilson J; Morrison B; Adams J; Schenkein D; Swift R
    J Clin Oncol; 2006 Feb; 24(6):937-44. PubMed ID: 16418495
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model.
    Grazziutti ML; Dong L; Miceli MH; Krishna SG; Kiwan E; Syed N; Fassas A; van Rhee F; Klaus H; Barlogie B; Anaissie EJ
    Bone Marrow Transplant; 2006 Oct; 38(7):501-6. PubMed ID: 16980998
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I-II evaluation of rapid sequence tandem high-dose melphalan with peripheral blood stem cell support in patients with multiple myeloma.
    Weaver CH; Zhen B; Schwartzberg LS; Leff R; Magee M; Geier L; Deaton K; Lewkow L; Buckner CD
    Bone Marrow Transplant; 1998 Aug; 22(3):245-51. PubMed ID: 9720737
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study.
    Berenson JR; Boccia R; Siegel D; Bozdech M; Bessudo A; Stadtmauer E; Talisman Pomeroy J; Steis R; Flam M; Lutzky J; Jilani S; Volk J; Wong SF; Moss R; Patel R; Ferretti D; Russell K; Louie R; Yeh HS; Swift RA
    Br J Haematol; 2006 Oct; 135(2):174-83. PubMed ID: 17010047
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thalidomide plus oral melphalan for advanced multiple myeloma: a phase II study.
    Offidani M; Marconi M; Corvatta L; Olivieri A; Catarini M; Leoni P
    Haematologica; 2003 Dec; 88(12):1432-3. PubMed ID: 14688003
    [No Abstract]   [Full Text] [Related]  

  • 36. Melphalan and dexamethasone for patients with multiple myeloma who are not candidates for autologous stem cell transplantation.
    Sharma A; Lokeshwar N; Raina V; Mohanti BK; Kumar R
    Natl Med J India; 2007; 20(3):121-4. PubMed ID: 17867615
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chronic myelomonocytic leukemia following prolonged alkylating agent therapy for multiple myeloma.
    Natazuka T; Yamaguchi T; Murayama T; Fukase M; Matsui T; Isobe T; Chihara K
    Int J Hematol; 1994 Dec; 60(4):263-5. PubMed ID: 7894029
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Toxicity in standard melphalan-prednisone therapy among myeloma patients with renal failure--a retrospective analysis and recommendations for dose adjustment.
    Carlson K; Hjorth M; Knudsen LM;
    Br J Haematol; 2005 Mar; 128(5):631-5. PubMed ID: 15725084
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Derivative (1;7)(q10;p10) in multiple myeloma. A sign of therapy-related hidden myelodysplastic syndrome.
    Ishii Y; Hsiao HH; Sashida G; Ito Y; Miyazawa K; Kodama A; Ohyashiki JH; Ohyashiki K
    Cancer Genet Cytogenet; 2006 Jun; 167(2):131-7. PubMed ID: 16737912
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outpatient high-dose melphalan in multiple myeloma patients.
    Kassar M; Medoff E; Seropian S; Cooper DL
    Transfusion; 2007 Jan; 47(1):115-9. PubMed ID: 17207239
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.